| 000 | 01198 a2200313 4500 | ||
|---|---|---|---|
| 005 | 20250516040415.0 | ||
| 264 | 0 | _c20111031 | |
| 008 | 201110s 0 0 eng d | ||
| 022 | _a1029-2403 | ||
| 024 | 7 |
_a10.3109/10428194.2011.566952 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTibes, Raoul | |
| 245 | 0 | 0 |
_aMyeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy? _h[electronic resource] |
| 260 |
_bLeukemia & lymphoma _cJul 2011 |
||
| 300 |
_a1178-87 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aJanus Kinase 2 _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aLeukemia _xdrug therapy |
| 650 | 0 | 4 |
_aMutation _xgenetics |
| 650 | 0 | 4 |
_aMyeloproliferative Disorders _xdrug therapy |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 |
_aPrimary Myelofibrosis _xdrug therapy |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xtherapeutic use |
| 700 | 1 | _aMesa, Ruben A | |
| 773 | 0 |
_tLeukemia & lymphoma _gvol. 52 _gno. 7 _gp. 1178-87 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.3109/10428194.2011.566952 _zAvailable from publisher's website |
| 999 |
_c20861373 _d20861373 |
||